CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Scheduled to Post Earnings on Monday
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) will be posting its quarterly earnings results on Monday, August 14th.
CASI Pharmaceuticals (NASDAQ:CASI) last posted its earnings results on Monday, May 15th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. On average, analysts expect CASI Pharmaceuticals to post $-0.13 EPS for the current fiscal year and $-0.19 EPS for the next fiscal year.
CASI Pharmaceuticals, Inc. (NASDAQ CASI) opened at 0.972 on Monday. The firm has a 50-day moving average price of $1.04 and a 200-day moving average price of $1.19. The firm’s market capitalization is $58.51 million. CASI Pharmaceuticals, Inc. has a 1-year low of $0.91 and a 1-year high of $1.76.
TRADEMARK VIOLATION WARNING: “CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Scheduled to Post Earnings on Monday” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/07/casi-pharmaceuticals-inc-nasdaqcasi-scheduled-to-post-earnings-on-monday.html.
A number of brokerages have weighed in on CASI. Maxim Group reiterated a “buy” rating and set a $4.00 price target on shares of CASI Pharmaceuticals in a report on Monday, April 17th. ValuEngine upgraded CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 13th.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.